[1]
|
M. Humbert, O. Sitbon and G. Simonneau, “Treatment of Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 351, No. 14, 2004, pp. 1425-1436. http://dx.doi.org/10.1056/NEJMra040291
|
[2]
|
J. R. Runo and J. E. Loyd, “Primary Pulmonary Hypertension,” The Lancet, Vol. 361, No. 9368, 2003, pp. 1533-1544. http://dx.doi.org/10.1016/S0140-6736(03)13167-4
|
[3]
|
G. E. D’Alonzo, R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, et al., “Survival in Patients with Primary Pulmonary Hypertension. Results from a National Prospective Registry,” Annals of International Medicine, Vol. 115, No. 5, 1991, pp. 343-349. http://dx.doi.org/10.7326/0003-4819-115-5-343
|
[4]
|
R. L. Benza, D. P. Miller, M. Gomberg-Maitland, R. P. Frantz, A. J. Foreman, C. S. Coffey, et al., “Predicting Survival in Pulmonary Arterial Hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (Reveal),” Circulation, Vol. 122, No. 2, 2010, pp. 164-172. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.898122
|
[5]
|
M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib, V. Gressin, et al., “Survival in Patients with Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era,” Circulation, Vol. 122, No. 2, 2010, pp. 156-163. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.911818
|
[6]
|
G. W. Mikhail, S. K. Prasad, W. Li, P. Rogers, A. H. Chester, S. Bayne, et al., “Clinical and Haemodynamic Effects of Sildenafil in Pulmonary Hypertension: Acute and Mid-Term Effects,” European Heart Journal, Vol. 25, No. 5, 2004, pp. 431-436. http://dx.doi.org/10.1016/j.ehj.2004.01.013
|
[7]
|
R. N. Channick, G. Simonneau, O. Sitbon, I. M. Robbins, A. Frost, V. F. Tapson, et al., “Effects of the Dual Endothelin-Receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Randomised Placebo-Controlled Study,” The Lancet, Vol. 358, No. 9288, 2001, pp. 1119-1123. http://dx.doi.org/10.1016/S0140-6736(01)06250-X
|
[8]
|
L. J. Rubin, D. B. Badesch, R. J. Barst, N. Galie, C. M. Black, A. Keogh, et al., “Bosentan Therapy for Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 346, No. 12, 2002, pp. 896-903. http://dx.doi.org/10.1056/NEJMoa012212
|
[9]
|
H. A. Ghofrani, O. Distler, F. Gerhardt, M. Gorenflo, E. Grunig, W. E. Haefeli, et al., “Treatment of Pulmonary Arterial Hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011,” International Journal of Cardiology, Vol. 154, Suppl. 1, 2011, pp. S20-S33. http://dx.doi.org/10.1016/S0167-5273(11)70490-9
|
[10]
|
G. A. Paul, J. S. Gibbs, A. R. Boobis, A. Abbas and M. R. Wilkins, “Bosentan Decreases the Plasma Concentration of Sildenafil When Coprescribed in Pulmonary Hypertension,” British Journal of Clinical Pharmacology, Vol. 60, No. 1, 2005, pp. 107-112. http://dx.doi.org/10.1111/j.1365-2125.2005.02383.x
|
[11]
|
N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, et al., “Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension,” The New England Journal of Medicine, Vol. 353, No. 20, 2005, pp. 2148-2157. http://dx.doi.org/10.1056/NEJMoa050010
|
[12]
|
G. Burgess, H. Hoogkamer, L. Collings and J. Dingemanse, “Mutual Pharmacokinetic Interactions between Steady-State Bosentan and Sildenafil,” European Journal of Clinical Pharmacology, Vol. 64, No. 1, 2008, pp. 43-50. http://dx.doi.org/10.1007/s00228-007-0408-z
|
[13]
|
P. L. van Giersbergen, C. Gnerre, A. Treiber, J. Dingemanse and U. A. Meyer, “Bosentan, a Dual Endothelin Receptor Antagonist, Activates the Pregnane X Nuclear Receptor,” European Journal of Pharmacology, Vol. 450, No. 2, 2002, pp. 115-121. http://dx.doi.org/10.1016/S0014-2999(02)02075-7
|
[14]
|
R. Hyland, E. G. Roe, B. C. Jones and D. A. Smith, “Identification of the Cytochrome P450 Enzymes Involved in the N-Demethylation of Sildenafil,” British Journal of Clinical Pharmacology, Vol. 51, No. 3, 2001, pp. 239-248. http://dx.doi.org/10.1046/j.1365-2125.2001.00318.x
|
[15]
|
J. Dingemanse and P. L. van Giersbergen, “Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist,” Clinical Pharmacokinetics, Vol. 43, No. 15, 2004, pp. 1089-1115. http://dx.doi.org/10.2165/00003088-200443150-00003
|
[16]
|
A. Viger-Chougnet, C. Funk and M. Pantze, “Drug-Drug Interactions with Bosentan (Ro 47-0203): In Vitro Studies of the Inhibition Potential of Bosentan on the Main Human Cytochrome P450 Isoenzymes,” 1997. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3775b2_08_biopharm.doc
|
[17]
|
G. J. Muirhead, D. J. Rance, D. K. Walker and P. Wastall, “Comparative Human Pharmacokinetics and Metabolism of Single-Dose Oral and Intravenous Sildenafil,” British Journal of Clinical Pharmacology, Vol. 53, Suppl. 1, 2002, pp. 13S-20S. http://dx.doi.org/10.1046/j.06-5251.2001.00028.x
|
[18]
|
A. Treiber, R. Schneiter, S. Hausler and B. Stieger, “Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil,” Drug Metabolism and Disposition, Vol. 35, No. 8, 2007, pp. 1400-1407. http://dx.doi.org/10.1124/dmd.106.013615
|
[19]
|
A. Treiber, R. Schneiter, S. Delahaye and M. Clozel, “Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 308, No. 3, 2004, pp. 1121-1129. http://dx.doi.org/10.1124/jpet.103.061614
|
[20]
|
Pfizer, “Revatio (Sildenafil) Tablets,” 1998. http://labeling.pfizer.com/showlabeling.aspx?id=645
|